The biggest recent advances in osteoporosis drug therapy are the bone-building (anabolic) medicines. These are teriparatide, abaloparatide, and romosozumab. Specialists have also learned to use them in a planned sequence: a bone-building drug first, then a drug that locks in the gain. For people at very high fracture risk, this approach raises bone density faster than older drugs alone. Bisphosphonates and denosumab remain the backbone of treatment for most patients.
Below, I set out how each drug class works, how the newer agents differ, and how clinicians decide what fits which patient.
Osteoporosis: A Quick Refresher
Osteoporosis is a skeletal disorder in which bone mass falls and the internal architecture weakens, so bones break with little force. Bone is constantly remodeled by two cell types. Osteoclasts remove old bone and osteoblasts lay down new bone. After menopause, falling estrogen speeds up osteoclast activity, so resorption outpaces formation.
Other risk factors include older age, family history of hip fracture, low body weight, smoking, heavy alcohol use, and long-term glucocorticoid (steroid) use. Low calcium and vitamin D intake and inactivity also contribute. Men are affected too and are often underdiagnosed.
Diagnosis rests on a DEXA scan (dual-energy X-ray absorptiometry). A T-score of −2.5 or lower at the hip or spine defines osteoporosis. A fragility fracture of the hip or spine establishes the diagnosis regardless of the T-score. The FRAX tool estimates 10-year fracture probability and helps decide who needs medicine.
How Osteoporosis Drugs Work: Two Strategies
Every osteoporosis medicine either slows bone breakdown or builds new bone. One drug does both.
| Drug class | Examples | How it works | How it is given |
|---|---|---|---|
| Bisphosphonates | Alendronate, risedronate, ibandronate, zoledronic acid | Antiresorptive: bind bone and inhibit osteoclasts | Weekly or monthly tablets; yearly IV infusion (zoledronic acid) |
| RANKL inhibitor | Denosumab | Antiresorptive: blocks the signal that forms osteoclasts | Injection every 6 months |
| SERM | Raloxifene | Estrogen-like effect on bone | Daily tablet |
| PTH analogs | Teriparatide, abaloparatide | Anabolic: stimulate osteoblasts to build new bone | Daily injection, usually for up to 2 years |
| Sclerostin inhibitor | Romosozumab | Dual action: increases formation and decreases resorption | Monthly injections for 12 months |
The Newer Agents: What Has Changed
Romosozumab
Romosozumab is a monoclonal antibody against sclerostin, a protein made by bone cells that normally puts the brakes on bone formation. Blocking it switches bone building on and reduces resorption at the same time. Bone density rises quickly over the 12-month course. Large clinical trials showed that it lowers fracture risk compared with placebo and with alendronate.
The catch is cardiovascular safety. Romosozumab carries a warning about heart attack and stroke. It is generally avoided in anyone who has had either event in the previous year, and it is used cautiously in people with other cardiovascular risk.
Teriparatide and Abaloparatide
These drugs mimic parts of parathyroid hormone. Given as a daily injection rather than a continuous level, they stimulate new bone formation, particularly in the spine. They are typically reserved for severe osteoporosis, multiple fractures, or fractures despite other treatment.
Denosumab and the “Rebound” Lesson
Denosumab is effective and convenient, but its effect wears off quickly if doses are delayed or stopped. Bone loss then accelerates, and the risk of multiple vertebral fractures rises. Clinicians now plan an exit: when denosumab is stopped, a bisphosphonate follows to hold the gains.
Sequencing: The Real Shift in Practice
The most important change is not a single drug but treatment order. When a bone-building agent is given first and followed by an antiresorptive, bone density gains are generally larger than the reverse order. Starting with an antiresorptive and switching later tends to blunt the anabolic response.
- Very high risk (recent fracture, multiple fractures, very low T-score): anabolic drug first, then a bisphosphonate or denosumab.
- High risk: an oral or IV bisphosphonate or denosumab as first-line therapy.
- After 3–5 years of a bisphosphonate: reassess. Lower-risk patients may take a monitored drug holiday, because these drugs persist in bone.
- Anabolic drug course complete: always follow with an antiresorptive, or the new bone is lost.
Complex cases are often managed with specialist input. Our article on treating osteoporosis with a rheumatologist explains when referral helps.
Safety and Side Effects
Rare but well-recognized side effects shape how long drugs are used:
- Osteonecrosis of the jaw: a rare non-healing area of jawbone, mostly after dental extractions. Dental work is ideally completed before starting treatment.
- Atypical femoral fractures: unusual thigh-bone fractures linked to long-term antiresorptive use. New thigh or groin pain should be reported.
- Stomach irritation with oral bisphosphonates, which must be taken upright on an empty stomach.
- Low calcium with denosumab or zoledronic acid, especially in people with kidney disease or low vitamin D.
For most people with osteoporosis, the fracture-prevention benefit clearly outweighs these small risks.
Foundations That Still Matter
No drug works well on an empty tank. Adequate calcium and vitamin D, weight-bearing and resistance exercise, fall prevention, stopping smoking, and limiting alcohol all support treatment. See our guide to the management of osteoporosis with supplements, and our osteoporosis guide for the wider picture.
Key Takeaways
- Bisphosphonates and denosumab remain first-line for most patients.
- Anabolic drugs (teriparatide, abaloparatide, romosozumab) build new bone and suit very-high-risk patients.
- Giving an anabolic drug first, then an antiresorptive, is the key practice advance.
- Denosumab should never be stopped without a follow-on plan.
- Romosozumab requires a check of cardiovascular history before use.
Frequently Asked Questions
What is the newest drug for osteoporosis?
Romosozumab is the newest drug class, a sclerostin inhibitor that both builds bone and reduces breakdown. It is given as monthly injections for one year. It is then followed by an antiresorptive medicine to maintain the gain.
Can osteoporosis medication reverse bone loss?
Anabolic drugs can meaningfully increase bone density and may move some patients out of the osteoporosis range. Antiresorptives mainly stop further loss and produce modest gains. Both reduce fracture risk, which is the real goal.
How long do I need to take osteoporosis drugs?
It depends on the drug and your risk. Bisphosphonates are usually reviewed after 3–5 years, and bone-building injections are given for a fixed course. Denosumab is continued until a planned switch. Treatment is best seen as long-term management with periodic review.
Are injections better than tablets for osteoporosis?
Not automatically. Injections suit people who cannot tolerate tablets, have absorption problems, or are at very high risk. Weekly tablets work well for many people who take them correctly.
